BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 23516357)

  • 21. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus.
    Carragher DM; Kaminski DA; Moquin A; Hartson L; Randall TD
    J Immunol; 2008 Sep; 181(6):4168-76. PubMed ID: 18768874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significant impact of sequence variations in the nucleoprotein on CD8 T cell-mediated cross-protection against influenza A virus infections.
    Zhong W; Liu F; Dong L; Lu X; Hancock K; Reinherz EL; Katz JM; Sambhara S
    PLoS One; 2010 May; 5(5):e10583. PubMed ID: 20485501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting M2e to DEC-205 induces an enhanced serum antibody-dependent heterosubtypic protection against influenza A virus infection.
    Padilla-Quirarte HO; Badillo-Godinez O; Gutierrez-Xicotencatl L; Acevedo-Betancur Y; Luna-Andon JD; Montiel-Hernandez JL; Lopez-Guerrero DV; Esquivel-Guadarrama F
    Vaccine; 2019 May; 37(19):2624-2633. PubMed ID: 30955979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain-Specific Hemagglutinin-Based or Cross-Protective M2 Extracellular Domain-Based Vaccination.
    Kim YJ; Kim KH; Ko EJ; Kim MC; Lee YN; Jung YJ; Lee YT; Kwon YM; Song JM; Kang SM
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30068650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heterosubtypic antiviral activity of hemagglutinin-specific antibodies induced by intranasal immunization with inactivated influenza viruses in mice.
    Muramatsu M; Yoshida R; Miyamoto H; Tomabechi D; Kajihara M; Maruyama J; Kimura T; Manzoor R; Ito K; Takada A
    PLoS One; 2013; 8(8):e71534. PubMed ID: 23977065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Establishment of functional influenza virus-specific CD8(+) T cell memory pools after intramuscular immunization.
    Wang Z; Chua BY; Ramos JV; Parra SM; Fairmaid E; Brown LE; Jackson DC; Kedzierska K
    Vaccine; 2015 Sep; 33(39):5148-54. PubMed ID: 26277069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms.
    Rangel-Moreno J; Carragher DM; Misra RS; Kusser K; Hartson L; Moquin A; Lund FE; Randall TD
    J Immunol; 2008 Jan; 180(1):454-63. PubMed ID: 18097047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protective efficacy of cross-reactive CD8+ T cells recognising mutant viral epitopes depends on peptide-MHC-I structural interactions and T cell activation threshold.
    Valkenburg SA; Gras S; Guillonneau C; La Gruta NL; Thomas PG; Purcell AW; Rossjohn J; Doherty PC; Turner SJ; Kedzierska K
    PLoS Pathog; 2010 Aug; 6(8):e1001039. PubMed ID: 20711359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus.
    LaMere MW; Lam HT; Moquin A; Haynes L; Lund FE; Randall TD; Kaminski DA
    J Immunol; 2011 Apr; 186(7):4331-9. PubMed ID: 21357542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterosubtypic cross-protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration.
    Budimir N; de Haan A; Meijerhof T; Gostick E; Price DA; Huckriede A; Wilschut J
    Influenza Other Respir Viruses; 2013 Nov; 7(6):1202-9. PubMed ID: 24102979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cross-protective immunity against influenza A/H1N1 virus challenge in mice immunized with recombinant vaccine expressing HA gene of influenza A/H5N1 virus.
    Yang S; Niu S; Guo Z; Yuan Y; Xue K; Liu S; Jin H
    Virol J; 2013 Sep; 10():291. PubMed ID: 24053449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice.
    Bodewes R; Kreijtz JH; Hillaire ML; Geelhoed-Mieras MM; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
    J Gen Virol; 2010 Jul; 91(Pt 7):1743-53. PubMed ID: 20335492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antigen-specific CD8(+) T cells persist in the upper respiratory tract following influenza virus infection.
    Wiley JA; Hogan RJ; Woodland DL; Harmsen AG
    J Immunol; 2001 Sep; 167(6):3293-9. PubMed ID: 11544317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development.
    Staneková Z; Varečková E
    Virol J; 2010 Nov; 7():351. PubMed ID: 21118546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine.
    Pandey A; Singh N; Vemula SV; Couëtil L; Katz JM; Donis R; Sambhara S; Mittal SK
    PLoS One; 2012; 7(3):e33428. PubMed ID: 22432020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines.
    Dong W; Bhide Y; Sicca F; Meijerhof T; Guilfoyle K; Engelhardt OG; Boon L; de Haan CAM; Carnell G; Temperton N; de Vries-Idema J; Kelvin D; Huckriede A
    Front Immunol; 2018; 9():2312. PubMed ID: 30356772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influenza A Virus Antibodies with Antibody-Dependent Cellular Cytotoxicity Function.
    Gao R; Sheng Z; Sreenivasan CC; Wang D; Li F
    Viruses; 2020 Mar; 12(3):. PubMed ID: 32121563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioinformatics design and experimental validation of influenza A virus multi-epitopes that induce neutralizing antibodies.
    Ramírez-Salinas GL; García-Machorro J; Rojas-Hernández S; Campos-Rodríguez R; de Oca AC; Gomez MM; Luciano R; Zimic M; Correa-Basurto J
    Arch Virol; 2020 Apr; 165(4):891-911. PubMed ID: 32060794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Both haemagglutinin-specific antibody and T cell responses induced by a chimpanzee adenoviral vaccine confer protection against influenza H7N9 viral challenge.
    Wang X; Fu W; Yuan S; Yang X; Song Y; Liu L; Chi Y; Cheng T; Xing M; Zhang Y; Zhang C; Yang Y; Zhu C; Zhang X; Xiong S; Xu J; Zhou D
    Sci Rep; 2017 May; 7(1):1854. PubMed ID: 28500340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.